A study to assess feasibility, efficacy and safety of Gemtuzumab ozogamicin in association with intensive chemotherapy CD33+ acute myeloid leukemia patients relapsing after a first allo-HCT
Latest Information Update: 09 Dec 2021
At a glance
- Drugs Gemtuzumab ozogamicin (Primary) ; Cytarabine; Daunorubicin; Mitoxantrone
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 21 Jul 2020 New trial record
- 21 Jun 2020 Results presented at the 25th Congress of the European Haematology Association